L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine
Immune Network
; : e19-2018.
Artículo
en Inglés
| WPRIM (Pacífico Occidental)
| ID: wpr-715079
Biblioteca responsable:
WPRO
ABSTRACT
Virus-like particles (VLPs) derived from human papillomavirus (HPV) L1 capsid proteins were used for HPV quadrivalent recombinant vaccine. The HPV quadrivalent vaccine is administrated in a 3-dose regimen of initial injection followed by subsequent doses at 2 and 6 months to prevent cervical cancer, vulvar, and vaginal cancers. The type 6, 11, 16, or 18 of HPV infection is associated with precancerous lesions and genital warts in adolescents and young women. The HPV vaccine is composed of viral L1 capsid proteins are produced in eukaryotic expression systems and purified in the form of VLPs. Four different the L1 protein of 3 different subtypes of HPV HPV11, HPV16, and HPV18 were expressed in Escherichia coli divided into 2 fragments as N- and C-terminal of each protein in order to examine the efficacy of HPV vaccine. Vaccinated sera failed to recognize N-terminal L1 HPV type 16 and type 18 by western blot while they detected N-terminal L1 protein of HPV type 11. Moreover, the recombinant C-terminal L1 proteins of type 16 was non-specifically recognized by the secondary antibody conjugated with horseradish peroxidase. This expression and purification system may provide simple method to obtain robust recombinant L1 protein of HPV subtypes to improve biochemical analysis of antigens with immunized sera.
Texto completo:
Disponible
Contexto en salud:
Enfermedades Desatendidas
Problema de salud:
Enfermedades Desatendidas
/
Zoonosis
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Papillomaviridae
/
Neoplasias Vaginales
/
Proteínas Recombinantes
/
Ensayo de Inmunoadsorción Enzimática
/
Condiloma Acuminado
/
Neoplasias del Cuello Uterino
/
Western Blotting
/
Proteínas de la Cápside
/
Escherichia coli
/
Peroxidasa de Rábano Silvestre
Límite:
Adolescente
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Immune Network
Año:
2018
Tipo del documento:
Artículo